GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (NAS:ORGS) » Definitions » Price-to-Owner-Earnings

Orgenesis (Orgenesis) Price-to-Owner-Earnings : (As of Apr. 25, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Orgenesis Price-to-Owner-Earnings?

As of today (2024-04-25), Orgenesis's share price is $0.504. Orgenesis does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Orgenesis's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Orgenesis was 3.44. The lowest was 1.06. And the median was 2.68.


ORGS's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.115
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-25), Orgenesis's share price is $0.504. Orgenesis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.61. Therefore, Orgenesis's PE Ratio for today is At Loss.

As of today (2024-04-25), Orgenesis's share price is $0.504. Orgenesis's EPS without NRI for the trailing twelve months (TTM) ended in was $-2.40. Therefore, Orgenesis's PE Ratio without NRI for today is At Loss.


Orgenesis Price-to-Owner-Earnings Historical Data

The historical data trend for Orgenesis's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Price-to-Owner-Earnings Chart

Orgenesis Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Orgenesis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Orgenesis's Price-to-Owner-Earnings

For the Biotechnology subindustry, Orgenesis's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Orgenesis's Price-to-Owner-Earnings falls into.



Orgenesis Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Orgenesis's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.504/-1.26
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orgenesis  (NAS:ORGS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Orgenesis Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Orgenesis's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis (Orgenesis) Business Description

Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.
Executives
Elliot Maltz officer: Chief Financial Officer C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Jacob Safier 10 percent owner C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Efrat Assa Kunik officer: Chief Development Officer C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky director JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips director C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber officer: Chief Scientific Officer 17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin director 7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler director 4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan officer: CEO 20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles 10 percent owner AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger 10 percent owner DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret officer: See Remarks 48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda director 2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452

Orgenesis (Orgenesis) Headlines

From GuruFocus